Robeco Institutional Asset Management B.V. Sells 2,624 Shares of Insulet Co. (NASDAQ:PODD)

Robeco Institutional Asset Management B.V. reduced its holdings in shares of Insulet Co. (NASDAQ:PODD) by 9.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,049 shares of the medical instruments supplier’s stock after selling 2,624 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Insulet were worth $5,597,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Diversified Trust Co grew its holdings in shares of Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after purchasing an additional 4,348 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Insulet by 349.3% in the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock worth $5,069,000 after buying an additional 22,993 shares during the period. Intech Investment Management LLC increased its holdings in shares of Insulet by 113.8% in the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after buying an additional 3,539 shares during the period. Natixis bought a new stake in shares of Insulet in the 1st quarter valued at about $3,610,000. Finally, Seven Eight Capital LP purchased a new stake in Insulet during the 1st quarter valued at about $1,418,000.

Insulet Price Performance

PODD opened at $268.00 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The company has a market cap of $18.79 billion, a price-to-earnings ratio of 48.73, a price-to-earnings-growth ratio of 4.47 and a beta of 1.22. The stock has a fifty day simple moving average of $232.01 and a two-hundred day simple moving average of $203.96. Insulet Co. has a 12-month low of $151.56 and a 12-month high of $275.52.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same quarter in the previous year, the business earned $0.38 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. Research analysts predict that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on PODD. Sanford C. Bernstein began coverage on Insulet in a research note on Wednesday. They issued an “outperform” rating and a $300.00 price target on the stock. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Barclays raised their price target on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Citigroup upped their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, UBS Group raised their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $246.80.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.